Market News How it works Learn FAQ
| RCT 0.1222 60.58% | NU 12.375 -18.37% | EWZ 33.44 -21.48% | TGL 0.2449 10.56% | BBD 2.87 -29.48% | SRTM 0.3384 -21.36% | ITUB 7.555 -21.87% | AZTR 1.72 140.56% | XP 15.775 -48.13% | NVD 4.02 -4.06% | SHFS 0.0979 -26.06% | SPCX 148.81 0.89% | CLRO 4.75 46.15% | SOXL 90.94 8.83% | GCDT 0.1442 -18.11% | PBR 22 -15.90% | NWGL 0.0822 0.24% | VALE 11.895 -4.07% | TSLL 10.9402 12.09% | INTC 90.94 4.58% | SGRY 23.095 46.63% | CRWV 56.79 4.71% | NVDA 215.6 2.20% | BITO 10.6301 -1.85% | GPUS 0.1862 10.24% | SOXS 47.855 -8.78% | RBNE 0.17 -10.53% | NOK 8.6738 6.56% | ABEV 2.78 -15.76% | RWM 14.455 -0.65% | IREN 26.12 4.88% | JBLU 2.2648 -13.72% | INTR 4.525 -37.07% | TSLG 5.4701 12.32% | SBS 4.615 -27.89% | TQQQ 68.649 3.56% | XTND 2.1 18.64% | SPRC 1.5 37.61% | SPDN 8.4901 -0.58% | TSLA 395.035 6.13% | AAL 12.1593 0.41% | LUCD 0.5437 32.29% | SID 0.9326 -20.97% | SQQQ 38.275 -3.54% | PBR-A 19.3171 -17.90% | CIFR 7.9 -0.50% | GGB 4.725 -7.35% | T 21.035 0.50% | QID 14.195 -2.44% | NFLX 63.265 -3.93%
PLProtalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. (PLX)

New York Stock Exchange Arca · Currency in USD
$2.48 ▼ -0.07 (-2.75%)
As of Oct 26, 1:14 PM ET. Market open.

Summary

Previous Close
$2.55
Open
$2.51
Day's Range
$2.46 – $2.52
52 Week Range
$1.65 – $3.19
Volume
264,229
Avg. Volume
761,015
Market Cap
$199.82M
Beta (5Y Monthly)
0.01
PE Ratio (TTM)
10.29
EPS (TTM)
$0.24
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$6.00

Profile: Protalix BioTherapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
226
CEO
Dror Bashan

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.02 · Revenue est. $12.41M
DateEst.Actual
Aug 12, 2026-$0.01$0.05Beat
May 13, 2026-$0.01$0.22Beat
Mar 18, 2026$0.01-$0.07Miss
Nov 13, 2025$0.06$0.03Miss
Aug 14, 2025$0.03$0.00Miss
May 9, 2025$0.08-$0.05Miss

Analyst view

Consensus price target
$6.00 ▲ +141.9%
Range $6.00 – $6.00
Rating: Buy
Buy 71% · Hold 29% · Sell 0%

Similar stocks

Get free alerts on PLX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.